NY-AQARA
11.7.2022 09:02:05 CEST | Business Wire | Press release
Aqara, a leading provider of smart home products, announced the wide availability of its Curtain Driver E1, a retrofit solution to automate traditional curtains. Build upon the Zigbee 3.0 protocol with improved reliability, range and energy efficiency, the curtain driver features a battery life of up to 12 months between each charge1 , and connects with other smart home accessories to enable truly automated home experiences2 . The Curtain Driver E1 has been made available on Amazon in both North America (US , Canada ) and Europe (UK , France , Germany , Italy , Spain ), as well as via selective Aqara retailers worldwide3 .
With two variants, namely the Rod Version for rods and the Track Version for U-rails and I-rails, the Aqara Curtain Driver E1 are compatible with a majority of curtains on the market. Thanks to its quiet-yet-powerful motor, heavier curtains of up to 12 kilograms can be pulled. It also features a wide compatibility with third-party ecosystems and voice assistants, including HomeKit/Siri, Alexa, Google Home/ Google Assistant, IFTTT, and the upcoming Matter standard will also be supported after its roll-out4 .
The installation is easy. Just mount the Curtain Driver E1 onto the curtain rod or rail, and no additional tools are required. The retrofit solution requires no new wiring to motorize the curtains, and the 6000mAh battery - which lasts for up to 1-year of use - can be charged via the Type-C port. It’s equipped with a built-in light sensor, allowing the curtain to close by its own when it’s too bright, and vice versa.
Apart from ambient brightness, the Curtain Driver can also be smartly controlled by other conditions, such as pre-set schedules, sunrise/sunset, local weather, and geofencing. For example the curtains open at sunset so that the beautiful view won’t be missed. When connect with other Aqara devices, more possibilities are made possible. Use a Wireless Mini Switch to open, close or stop the curtain by a simple press, or adjust the precise opening by turning the Cube. The Camera Hub G3 even allows the curtain to be controlled with hand gestures.
The Curtain Driver is designed with high flexibility to suit for different scenarios and use cases. Device grouping is supported, so that double sided curtains can be controlled simultaneously. The speed of the curtain driver is adjustable, and the device can be configured to work more quietly in the mornings so that the sleep won’t be interrupted anymore. Moreover, it’s possible to set the duration time for curtain movements, for example to pull the curtain from closed to fully open in an hour, which simulates a natural sunrise.
In celebration of the launch, Aqara now offers a 20% discount for the new device on Amazon. North American customers will enjoy the offer with the promo code USCURTAIN in the US and Canada , while European customers will enjoy it using the promo code CURTAINUKEU in France , Germany , Italy , Spain and the UK . Both codes are valid on July 11th , 2022. And Amazon Prime members will continue to enjoy the discount from July 12th to 13th with no promo code required.
For more details of the Curtain Driver E1, please visit our website .
1. Based on the lab test of two devices on the double panel curtains. The actual battery life may vary, depending on curtain weight, track length, and friction.
2. A Zigbee 3.0 Aqara hub is required.
3. Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
4. An OTA update of the compatible Aqara hub is required.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005076/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom